Merck is financing a $1.85 million study being conducted at Texas Tech University to see if lower dosages of its lucrative but controversial cattle growth drug Zilmax could allow the company to reintroduce the product to U.S. and global markets and kick-start sales.
Harvard University engineer David Mooney believes there may be a link between immunotherapy and sterilization. He recently received a $700,000 grant to develop a contraceptive vaccine for pets.
Researchers at Curtin University's Biotechnology and Drug Development Research Laboratory in Perth, Australia, are developing a microcapsule formulation that they say improves the drug delivery and absorption of diabetes drugs.
President Obama has pushed precision medicine and cybersecurity into the national consciousness and toward the top of the legislative agenda. Obama referred to both topics in his State of the Union address, but at this stage more is known about the cybersecurity plan.
GlaxoSmithKline has shipped out the first batch of its in-development Ebola vaccine, expecting to kick off late-stage studies in the coming weeks.
EndoGastric Solutions is awaiting the outcome of a CPT code meeting to enable payer reimbursement for its transoral gastroesophageal reflux disease (GERD) surgical device within the next few weeks. In the meantime, the startup has released data on the transoral incisionless fundoplication (TIF) procedure in the latest issue of the journal Gastroenterology.
Kite Pharma, contending with a slew of rivals in the newfangled field of immuno-oncology, has aligned itself with a pioneer in the field, teaming up with an Israeli university to work on treatments that train the body's own defenses on cancerous growth.
Noninvasive hemodynamic monitoring company Cheetah Medical is touting results from a new study showing that using the company's technology to assess fluid responsiveness could save hospitals time and money.
Medtronic's MiniMed 640G insulin pump is now available in Australia, with additional launches pending local approval. The company says the device represents the latest march toward the development of an artificial pancreas.
Brent Saunders, Actavis chief executive and architect of four major pharma deals, doesn't hate drug discovery. He just doesn't want his company to do it.